Evotec SE

Evotec SE is a drug discovery and development company headquartered in Hamburg, Germany. Founded in 1993 as Evotec BioSystems GmbH — with Nobel Laureate Manfred Eigen among its founders — it converted to a Societas Europaea structure in April 2019. The company trades on Frankfurt's TecDAX/MDAX under the ticker EVT and completed a secondary Nasdaq listing in November 2021 (ticker: EVO), raising $500 million.

Evotec operates in two segments — Shared R&D and Just–Evotec Biologics — discovering and developing small molecule drugs across oncology, neurology, nephrology, cardiovascular, inflammation, metabolic, and respiratory diseases. Its business model preserves pipeline upside through royalties, milestones, and equity stakes, with partners typically bearing clinical development costs. The company employs approximately 4,757 people and reports customer retention rates above 90% in each of the last three years.

Key collaborators include Mass General Brigham, Joslin Diabetes Center, Novo Nordisk, Pfizer, Bristol Myers Squibb, and universities such as Oxford, Harvard, Yale, and Johns Hopkins. As of December 2025, Evotec has 62 active partnered projects and 31 eligible for future partnering. Full-year 2024 revenues reached €797 million, with 2025 guidance of €840–880 million and a 2028 target revenue CAGR of 8–12% alongside an EBITDA margin above 20%.

As a company at the intersection of drug discovery technology and broad pharmaceutical partnership networks, Evotec is directly relevant to innovations in AI-driven drug discovery, biologics manufacturing, and early-stage R&D efficiency — areas that could accelerate its pipeline and partnership value proposition.